Literature DB >> 25309095

Intra-abdominal inflammatory myofibroblastic tumor: spontaneous regression.

Jun-Jie Zhao1, Jia-Qian Ling1, Yong Fang1, Xiao-Dong Gao1, Ping Shu1, Kun-Tang Shen1, Jing Qin1, Yi-Hong Sun1, Xin-Yu Qin1.   

Abstract

Inflammatory myofibroblastic tumors are usually treated by surgical resection. We herein report two cases of intra-abdominal inflammatory myofibroblastic tumors that were unresectable and underwent spontaneous regression without any treatment. Our case report and literature review show that regression is more common in the middle-aged and older male populations. Abdominal discomfort and fever were the most common symptoms, but the majority of patients had no obvious physical signs. There was no specific indicator for diagnosis. The majority of the lesions regressed within 3 mo and nearly all of the masses completely resolved within 1 year. We conclude that the clinical characteristics of inflammatory myofibroblastic tumors are variable and, accordingly, the disease needs to be subdivided and treated on an individual basis. Surgery is always the first-line treatment; however, for those masses assessed as unresectable, conservative therapy with intense follow-up should be considered.

Entities:  

Keywords:  Abdominal cavity; Inflammatory myofibroblastic tumor; Inflammatory pseudotumor; Spontaneous regression

Mesh:

Year:  2014        PMID: 25309095      PMCID: PMC4188916          DOI: 10.3748/wjg.v20.i37.13625

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Spontaneous regression of hepatic pseudotumor.

Authors:  P Gollapudi; G Chejfec; E J Zarling
Journal:  Am J Gastroenterol       Date:  1992-02       Impact factor: 10.864

2.  Inflammatory myofibroblastic tumor with ALK/TPM3 fusion presenting as ileocolic intussusception: an unusual presentation of an unusual neoplasm.

Authors:  Anya N A Milne; Karl J Sweeney; Diarmuid S O'Riordain; Patrick Pauwels; Maria Debiec-Rychter; G Johan A Offerhaus; Michael Jeffers
Journal:  Hum Pathol       Date:  2005-11-28       Impact factor: 3.466

Review 3.  Inflammatory pseudotumours of the liver: a spectrum of presentation and management options.

Authors:  P J Goldsmith; A Loganathan; M Jacob; N Ahmad; G J Toogood; J P A Lodge; K R Prasad
Journal:  Eur J Surg Oncol       Date:  2009-06-09       Impact factor: 4.424

4.  The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study.

Authors:  Harry Applebaum; Mark W Kieran; Timothy P Cripe; Cheryl M Coffin; Margaret H Collins; Arja Kaipainen; Andrea Laforme; Robert C Shamberger
Journal:  J Pediatr Surg       Date:  2005-06       Impact factor: 2.545

5.  Inflammatory pseudotumor of the liver: case report and review of literature.

Authors:  Megumi Motojuku; Yasuhisa Oida; Goryu Morikawa; Tatsuhiko Hoshikawa; Tomoki Nakamura; Takayuki Tajima; Masaya Mukai; Hiroyuki Otsuka; Kazuki Akieda; Kenichi Hirabayashi; Hiroyasu Makuuchi; Sadaki Inokuchi
Journal:  Tokai J Exp Clin Med       Date:  2008-07-20

6.  Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors.

Authors:  J W Hussong; M Brown; S L Perkins; L P Dehner; C M Coffin
Journal:  Mod Pathol       Date:  1999-03       Impact factor: 7.842

7.  Inflammatory pseudotumor of the liver: demographics, diagnosis, and the case for nonoperative management.

Authors:  Jonathan B Koea; Grant W Broadhurst; Michael S Rodgers; John L McCall
Journal:  J Am Coll Surg       Date:  2003-02       Impact factor: 6.113

8.  [Periureteral inflammatory pseudotumor: a case report].

Authors:  Go Tanikawa; Natsuki Takaha; Norio Nonomura; Akihiko Okuyama
Journal:  Hinyokika Kiyo       Date:  2003-10

Review 9.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

10.  A new case of spontaneous regression of inflammatory hepatic pseudotumor.

Authors:  Hichem Jerraya; Slim Jarboui; Hassen Daghmoura; Abdeljelil Zaouche
Journal:  Case Rep Med       Date:  2011-03-22
View more
  7 in total

1.  A unique case of inflammatory myofibroblastic tumor of the liver manifesting with biloma: A case report.

Authors:  Kun Huang; Pingwu Zhao; Jiangying Zhao; Pan Zhao; Jian Yang
Journal:  Oncol Lett       Date:  2022-05-26       Impact factor: 3.111

2.  Inflammatory myofibroblastic tumour: an unusual presentation including small bowel obstruction and palpable abdominal mass.

Authors:  Emily Cerier; Eliza Wright Beal; Mary E Dillhoff
Journal:  BMJ Case Rep       Date:  2018-05-15

3.  Inflammatory myofibroblastic tumors arising from pancreas head and peri-splenic area mimicking a malignancy.

Authors:  Eun Jeong Jang; Kwan Woo Kim; Sung Hwa Kang; Min Gyoung Pak; Song Hee Han
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-05-31

4.  Spontaneous Regression of Inflammatory Pseudotumor in the Cauda Equina: A Case Report.

Authors:  Kazuhiro Yoshimura; Manabu Sasaki; Masaru Kojima; Kouichirou Tsuruzono; Katsumi Matsumoto; Akatsuki Wakayama; Toshiki Yoshimine
Journal:  NMC Case Rep J       Date:  2016-09-07

5.  A Pancreatic Inflammatory Myofibroblastic Tumor with Spontaneous Remission: A Case Report with a Literature Review.

Authors:  Hiroyuki Matsubayashi; Katsuhiko Uesaka; Keiko Sasaki; Seitaro Shimada; Kazunori Takada; Hirotoshi Ishiwatari; Hiroyuki Ono
Journal:  Diagnostics (Basel)       Date:  2019-10-17

6.  Inflammatory Myofibroblastic Tumor of Common Bile Duct in a Girl.

Authors:  Aureen D'Cunha; Susan Jehangir; Reju Thomas
Journal:  APSP J Case Rep       Date:  2016-09-01

7.  Remission of ALK-negative primary pulmonary inflammatory myofibroblastic tumor on treatment with clarithromycin: A case report and review of the literature.

Authors:  Hidehiro Watanabe; Tomonori Uruma; Gen Tazaki; Takuma Tajiri; Ryota Kikuchi; Masayuki Itoh; Kazutetsu Aoshiba; Hiroyuki Nakamura
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.